These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 15344542)

  • 61. Assessment of clinical severity and investigation of uncomplicated gastroesophageal reflux disease and noncardiac angina-like chest pain.
    Lemire S
    Can J Gastroenterol; 1997 Sep; 11 Suppl B():37B-40B. PubMed ID: 9347176
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The diagnosis of gastroesophageal reflux disease.
    Dughera L; Navino M; Cassolino P; Pellicano R
    Minerva Gastroenterol Dietol; 2007 Jun; 53(2):143-52. PubMed ID: 17557042
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Endoluminal Therapy for Gastroesophageal Reflux Disease: In Between the Pill and the Knife?
    Brar TS; Draganov PV; Yang D
    Dig Dis Sci; 2017 Jan; 62(1):16-25. PubMed ID: 27796767
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gastroesophageal reflux disease: an Asian perspective.
    Wu JC
    J Gastroenterol Hepatol; 2008 Dec; 23(12):1785-93. PubMed ID: 19120871
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression.
    Abdul-Hussein M; Freeman J; Castell D
    Pharmacotherapy; 2015 Dec; 35(12):1124-9. PubMed ID: 26621819
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Gastroesophageal reflux disease. Control of symptoms, prevention of complications.
    Kaynard A; Flora K
    Postgrad Med; 2001 Sep; 110(3):42-4, 47-8, 51-3. PubMed ID: 11570205
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Pathophysiology and treatment of non-erosive reflux disease].
    Oshima T; Miwa H
    Nihon Shokakibyo Gakkai Zasshi; 2009 Mar; 106(3):327-34. PubMed ID: 19262046
    [No Abstract]   [Full Text] [Related]  

  • 69. Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring.
    Kohata Y; Fujiwara Y; Machida H; Okazaki H; Yamagami H; Tanigawa T; Watanabe K; Watanabe T; Tominaga K; Arakawa T
    J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():58-62. PubMed ID: 22486873
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment.
    Franciosi JP; Mougey EB; Williams A; Gomez Suarez RA; Thomas C; Creech CL; George K; Corao D; Lima JJ
    Eur J Pediatr; 2018 Jan; 177(1):69-77. PubMed ID: 29209919
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine.
    Miyamoto M; Haruma K; Kuwabara M; Nagano M; Okamoto T; Tanaka M
    J Gastroenterol Hepatol; 2007 May; 22(5):639-44. PubMed ID: 17444849
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Does Helicobacter pylori infection contribute to gastroesophageal reflux disease?
    Spechler SJ
    Yale J Biol Med; 1998; 71(2):143-8. PubMed ID: 10378360
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pathophysiology of Gastroesophageal Reflux Disease.
    Tack J; Pandolfino JE
    Gastroenterology; 2018 Jan; 154(2):277-288. PubMed ID: 29037470
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nocturnal acid breakthrough and esophageal acidification during treatment with dexlansoprazole as compared to omeprazole in patients with gastroesophageal reflux disease.
    Ghoshal UC; Blaachandran A; Rai S; Misra A
    Indian J Gastroenterol; 2022 Aug; 41(4):405-414. PubMed ID: 35771390
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Nocturnal acid breakthrough: pH, drugs and bugs.
    Tutuian R; Katz PO; Castell DO
    Eur J Gastroenterol Hepatol; 2004 May; 16(5):441-3. PubMed ID: 15097034
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Refractory GERD: what is it?
    Fass R; Gasiorowska A
    Curr Gastroenterol Rep; 2008 Jun; 10(3):252-7. PubMed ID: 18625135
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A prospective study of gastric acid analysis and esophageal acid exposure in patients with gastroesophageal reflux refractory to medical therapy.
    Ahlawat SK; Mohi-Ud-Din R; Williams DC; Maher KA; Benjamin SB
    Dig Dis Sci; 2005 Nov; 50(11):2019-24. PubMed ID: 16240209
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Gastroesophageal reflux disease: pathogenetic basis of differentiated tactics of treatment].
    Tkachenko EI; Uspenskiĭ IuP; Karateev AE; Bakulin IG; Pakhomova IG
    Eksp Klin Gastroenterol; 2009; (2):104-14. PubMed ID: 19552028
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Medical management of patients with esophageal or supraesophageal gastroesophageal reflux disease.
    Richter JE
    Am J Med; 2003 Aug; 115 Suppl 3A():179S-187S. PubMed ID: 12928099
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Epidemiology and clinical characteristics of GERD in the Japanese adults].
    Fujiwara Y
    Nihon Rinsho; 2016 Aug; 74(8):1257-1261. PubMed ID: 30562425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.